Hepcidin
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| hepcidin antimicrobial peptide
| |
| Identifiers | |
| Symbol | HAMP |
| Entrez | 57817 |
| HUGO | 15598 |
| OMIM | 606464 |
| RefSeq | NM_021175 |
| UniProt | P81172 |
| Other data | |
| Locus | Chr. 19 q13.1 |
| Cardiology Network |
 Discuss Hepcidin further in the WikiDoc Cardiology Network |
| Adult Congenital |
|---|
| Biomarkers |
| Cardiac Rehabilitation |
| Congestive Heart Failure |
| CT Angiography |
| Echocardiography |
| Electrophysiology |
| Cardiology General |
| Genetics |
| Health Economics |
| Hypertension |
| Interventional Cardiology |
| MRI |
| Nuclear Cardiology |
| Peripheral Arterial Disease |
| Prevention |
| Public Policy |
| Pulmonary Embolism |
| Stable Angina |
| Valvular Heart Disease |
| Vascular Medicine |
| WikiDoc Cardiology News |
 Read more about Hepcidin in the WikiDoc Cardiology News |
| All News Articles |
|---|
| Acute Coronary Syndromes |
| Biomarkers |
| Cardiovascular Imaging |
| CT Surgery |
| Diabetes |
| Electrophysiology |
| General Cardiology |
| Guidelines |
| Health Policy |
| Heart Failure |
| Hypertension |
| Interventional |
| Peripheral Arterial Disease |
| Prevention |
| Valvular Heart Disease |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Hepcidin is a recently discovered peptide hormone produced by the liver, that appears to be the master regulator of iron homeostasis in humans and other mammals.[1]
The peptide that would later become known as hepcidin was first reported as LEAP-1, for Liver-Expressed Antimicrobial Protein [1]. Independently, in a search for antimicrobial peptides, researchers working in the lab of Tomas Ganz discovered a peptide associated with inflammation, and named it "hepcidin" after observing that it was produced in the liver ("hep-") and appeared to have bacteriocidal properties ("-cidin" for "killing")[1]. Both groups were focused on the antimicrobial properties of the peptide. HAMP is the gene that encodes for hepcidin.
Soon after this discovery, researchers discovered that hepcidin production in mice increased in conditions of iron overload as well as in inflammation. Genetically modified mice engineered to overexpress hepcidin died shortly after birth with severe iron deficiency, again suggesting a central and not redundant role in iron regulation. The first evidence that linked hepcidin to the clinical condition known as the anemia of inflammation came from the lab of Nancy Andrews in Boston when researchers looked at tissue from two patients with liver tumors with a severe microcytic anemia that did not respond to iron supplementation. The tumor tissue appeared to be overproducing hepcidin, and contained large quantities of hepcidin mRNA. Removing the tumors surgically cured the anemia.
Taken together, these discoveries suggested that hepcidin regulated the release of iron in the body.
More recent discoveries have shown that hepcidin directly interacts with ferroportin, a protein that transports iron out of cells that store it. This is another confirmation that hepcidin is directly involved in iron homeostasis. Furthermore, several mutations in hepcidin have been found that result in juvenile hemochromatosis. The majority of juvenile hemochromatosis cases are due to mutations in hemojuvelin, a regulator of hepcidin production.
Hepcidin has shown fairly consistent activity against fungi. Hepcidin's antibacterial activity currently seems to be inconsistent. The current scientific evidence suggests that hepcidin is a central regulatory hormone and its main action is to regulate systemic iron homeostasis.
External links
- Camaschella C (2005). "Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders". Blood 106 (12): 3710-7. doi:10.1182/blood-2005-05-1857. PMID 16030190.
- MeSH hepcidin
References
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
